


Discover & Deliver: Frontrunners in the Coronavirus Vaccine Race



As the race continues to develop a COVID-19 vaccine, three frontrunners have emerged. While there are currently [nine vaccines](#) in late-stage Phase III clinical trials, the vaccine candidates produced by AstraZeneca, Pfizer, and Moderna are widely regarded as the most promising.

Just as the vaccines have been developed at an unprecedented speed, the companies are taking unprecedented steps to ensure transparency and to ease concerns about the safety and efficacy of a potential COVID-19 vaccine.

What's new? Over the last week, [AstraZeneca](#), [Pfizer](#), and [Moderna](#) released detailed blueprints describing the process for selecting and monitoring participants in the clinical trials and the clinical endpoints that must be reached to determine if the vaccine candidate is truly effective.

The blueprints also seek to answer the question at the top of everyone's minds: When will we have a vaccine to defeat COVID-19?

What's next? To receive emergency use authorization (EUA) from the Food and Drug Administration (FDA), the companies must show that the vaccine is at least 50% effective. Each

company must illustrate that a certain number of infections have occurred to surpass that threshold.

For Moderna, [the company estimates](#) they will know if their vaccine is effective by December at the earliest; for Pfizer in July; and for AstraZeneca, the timing is a bit unclear. While AstraZeneca restarted its Phase 3 trial in the [UK, South Africa, and Brazil](#), the trial remains on hold in the United States.

The big picture: Despite the difference in timing, one thing remains clear: the business community continues to lead the way to develop COVID-19 solutions. With the world's top innovative and scientific minds on the task, we remain confident we will discover and deliver an effective COVID-19 vaccine soon.

—Jonathan Weinberger, Executive Vice President, Global Innovation Policy Center